about
Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.Clinical trial enrollment of adolescents and young adults with sarcoma.Pediatric oncology enters an era of precision medicine.Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research.Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience.Neuropsychological functioning of children treated with intensive chemotherapy followed by myeloablative consolidation chemotherapy and autologous hematopoietic cell rescue for newly diagnosed CNS tumors: an analysis of the Head Start II survivors.Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.Emerging and investigational therapies for neuroblastoma.Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumabPhase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancerIdentification of a secondary RET mutation in a pediatric patient with relapsed acute myeloid leukemia leads to the diagnosis and treatment of asymptomatic metastatic medullary thyroid cancer in a parent: a case for sequencing the germline.Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group StudyNutritional status and clinical outcomes in pediatric patients with solid tumors : A systematic review of the literature
P50
Q33553516-58A50309-E1D2-48B8-83C9-7ACCFCD8624AQ34543413-C0D3E4C0-BC18-4DA2-8FC7-148220F3ECF8Q35599819-4025AD3F-9BA0-40CF-BAB1-A216A3A28CDDQ35943388-680AC3B9-AD5F-4BFE-BF9C-22B956A3FD06Q37529593-C7013D3F-0DFB-4CCB-8653-8C679BEB2FFDQ38685233-C4A6E4EC-7EDD-4E1D-BFD8-B4EA4AC2CB36Q38739623-2EC490F6-D48E-4F4D-B42D-0E7B56D3605EQ39022681-D4532295-6C98-48EC-A753-15A89090BEECQ47178067-A1A099E2-7B08-466D-90F7-2522F6CDAADEQ48354967-31885AAE-2F3D-463D-B0EF-6C944C9F16E0Q48368768-5A493012-9EBC-4034-AFC9-CB1D954D964FQ50073387-7FA793AD-02C7-4484-B28A-C3DED9623817Q52722728-A3CA3303-DD9B-4BB4-835A-E5FB762C4F42Q58098172-6F2AD2E5-0DEF-44E3-A7C3-ADEC314D3BCBQ61760830-93F0E6C5-2B24-4A12-A658-2A004129E7EEQ64916589-C54263C5-292C-4FE2-8168-1C26009DB7E7Q80508800-EAB6A09D-DC06-4204-8A43-FDEC12232F7EQ91097002-74217CCD-E171-4F34-A7FF-7108E044A01A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Julia L Glade Bender
@ast
Julia L Glade Bender
@en
Julia L Glade Bender
@es
Julia L Glade Bender
@nl
type
label
Julia L Glade Bender
@ast
Julia L Glade Bender
@en
Julia L Glade Bender
@es
Julia L Glade Bender
@nl
prefLabel
Julia L Glade Bender
@ast
Julia L Glade Bender
@en
Julia L Glade Bender
@es
Julia L Glade Bender
@nl
P106
P1153
8756439000
P21
P31
P496
0000-0001-5316-6440